These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 8790024

  • 1. Differential dose-response to oral xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention.
    Kereiakes DJ, Runyon JP, Kleiman NS, Higby NA, Anderson LC, Hantsbarger G, McDonald S, Anders RJ.
    Circulation; 1996 Sep 01; 94(5):906-10. PubMed ID: 8790024
    [Abstract] [Full Text] [Related]

  • 2. Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment.
    Kereiakes DJ, Kleiman N, Ferguson JJ, Runyon JP, Broderick TM, Higby NA, Martin LH, Hantsbarger G, McDonald S, Anders RJ.
    Circulation; 1997 Aug 19; 96(4):1117-21. PubMed ID: 9286938
    [Abstract] [Full Text] [Related]

  • 3. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial.
    Kereiakes DJ, Kleiman NS, Ferguson JJ, Masud AR, Broderick TM, Abbottsmith CW, Runyon JP, Anderson LC, Anders RJ, Dreiling RJ, Hantsbarger GL, Bryzinski B, Topol EJ.
    Circulation; 1998 Sep 29; 98(13):1268-78. PubMed ID: 9751674
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab.
    Mascelli MA, Kleiman NS, Marciniak SJ, Damaraju L, Weisman HF, Jordan RE.
    Am Heart J; 2000 Apr 29; 139(4):696-703. PubMed ID: 10740154
    [Abstract] [Full Text] [Related]

  • 5. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA.
    Am Heart J; 1998 Apr 29; 135(4):S43-55. PubMed ID: 9539495
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
    Christ G, Hafner T, Siller-Matula JM, Francesconi M, Grohs K, Wilhelm E, Podczeck-Schweighofer A.
    Thromb Res; 2013 Jul 29; 132(1):e36-41. PubMed ID: 23791395
    [Abstract] [Full Text] [Related]

  • 12. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
    Greenbaum AB, Grines CL, Bittl JA, Becker RC, Kereiakes DJ, Gilchrist IC, Clegg J, Stankowski JE, Grogan DR, Harrington RA, Emanuelsson H, Weaver WD.
    Am Heart J; 2006 Mar 29; 151(3):689.e1-689.e10. PubMed ID: 16504633
    [Abstract] [Full Text] [Related]

  • 13. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.
    Ibbotson T, McGavin JK, Goa KL.
    Am J Cardiovasc Drugs; 2003 Mar 29; 3(5):381-6. PubMed ID: 14728074
    [Abstract] [Full Text] [Related]

  • 14. Oral blockade of the platelet glycoprotein IIb/IIIa receptor: fact or fancy?
    Kereiakes DJ.
    Am Heart J; 1999 Jul 29; 138(1 Pt 2):S39-46. PubMed ID: 10385790
    [Abstract] [Full Text] [Related]

  • 15. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
    Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, Kleiman NS, Booth JE, Balog C, Cabot CF, Anderson KM, Weisman HF, Topol EJ.
    Circulation; 1999 Apr 20; 99(15):1951-8. PubMed ID: 10208997
    [Abstract] [Full Text] [Related]

  • 16. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.
    Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, Ivanhoe RJ, Wang AL, Miller DP, Anderson KM, Califf RM.
    JAMA; 1997 Aug 13; 278(6):479-84. PubMed ID: 9256222
    [Abstract] [Full Text] [Related]

  • 17. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
    Holmes LE, Gupta R, Rajendran S, Luu J, French JK, Juergens CP.
    Cardiovasc Ther; 2016 Oct 13; 34(5):330-6. PubMed ID: 27327862
    [Abstract] [Full Text] [Related]

  • 18. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell RM, Dillard P, Davidian M, Zhang D, Cantor WJ, Sketch MH, Ohman EM, Zidar JP, Gretler D, DiBattiste PM, Tcheng JE, Califf RM, Harrington RA.
    Circulation; 2002 Sep 17; 106(12):1470-6. PubMed ID: 12234950
    [Abstract] [Full Text] [Related]

  • 19. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade.
    Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE.
    Circulation; 1998 May 05; 97(17):1680-8. PubMed ID: 9591761
    [Abstract] [Full Text] [Related]

  • 20. Pharmacodynamic profile of short-term readministration of abciximab in healthy subjects.
    Freedman J, Mascelli MA, Pezzullo JC, Barnathan ES, Frederick B, Jordan RE, Abernethy DR.
    Am Heart J; 2002 Jan 05; 143(1):87-94. PubMed ID: 11773917
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.